Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Sep 25, 2023 4:30pm
259 Views
Post# 35653195

Where should the stock price be now?

Where should the stock price be now?THTX is down 40-50% or so since it last announced earnings in July. SInce then it has:

1.) Had a reverse split on its stock which is a menaingless accounting entry

2.) Taken its cash holdings quickly back up to $22.9 million after falling below $20 million in early July, thereby eliminating any concern about the 10/31/23 deadline to be above $20 million.

3.) Announced it has reached adjusted EBITDA positive earlier than anticipated

4.) FIled the F8 version of Egrifta on time, which will almost certainly be approved, thereby providing another 10 years or so of patent protection for the company's most important drug

5.) Restarted the TH-1902 trial, admittedly behind the original schedule and with no patients dosed yet. Still the trial is in process.

6.) Renegotiated the terms of its Marathon loan to eliminate some potential problems and free up cash as progress is made on adjusted EBITDA

So, is it just me or does it seem like there may be a serious inefficency in the way the stock has been priced over the last three months. That is a lot of progress and the stock has only suffered. It makes little sense to me. If others begin to realize this is screwed up, the stock could and should have another big move higher.  
<< Previous
Bullboard Posts
Next >>